Table III.

Estimated change in peak E₂ (pg/ml) by urinary BPA quartiles among 174 women (237 IVF cycles).

Covariates	Unadjusted			Adjusteda (n = 173 women, 236 cycles)			Protocol adjustedb (n = 172 women, 235 cycles)
	Change in mean	95% CI	P-value	Change in mean	(95% CI)	P-value	Change in mean	(95% CI)	P-value
BPA quartiles (range µg/l)
Q1 (≤1.60)	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Q2 (1.61–2.32)	−64	−370, 242	0.68	−40	−343, 262	0.79	−38	−340, 264	0.80
Q3 (2.33–3.76)	−244	−552, 64	0.12	−253	−556, 49	0.10	−255	−556, 47	0.10
Q4 (≥3.77)	−441	−753, −130	0.006	−471	−776, −165	0.003	−408	−719, −97	0.01
Test for trend (P-value)c	0.004			0.001			0.005
Age (≥37 versus <37 years)	−201	−454, 52	0.12	−144	−386, 98	0.24	−25	−284, 234	0.85
BMI* (≥25 versus <25 kg/m2)	−246	−506, 14	0.06	−252	−506, 0.8	0.05	−244	−493, 5.4	0.06
Day 3 FSH (≥12 versus <12 IU/l)	−604	−1304, 97	0.09	−597	−1272, 72	0.08	−495	−1167, 178	0.15
IVF protocol (flare/ant. versus luteal)	−425	−662, −188	<0.001	—	—	—	−302	−564, −40	0.02
Ever versus never smoker	−32	−313, 249	0.82	—	—	—	—	—	—

BPA, Bisphenol A; Day 3 FSH, FSH on 3rd day of menses, Q1, first quartile; Q2, second quartile, Q3, third quartile; Q4, fourth quartile, 95% CI, 95% confidence intervals; flare/ant., flare or GnRH antagonist protocol *1 missing value.

^aAdjusted for age, BMI, Day 3 FSH, using mixed models to account for correlated outcomes.

^bAdjusted for age, BMI, Day 3 FSH, protocol (flare/antagonist versus regular luteal phase protocol).

^cTest for linear trend based on ordinal quartiles.